



Cardiopatías en Síndrome de Transfusión Feto-fetal (STFF)


Dr. Pablo Silva Labarca
Becado Medicina Materno Fetal
Universidad de Chile

Introducción


- El síndrome de transfusión feto-fetal (STFF) se caracteriza por un desbalance hemodinámico provocado por anastomosis vasculares placentarias.
- **Feto donante:** Hipovolemia, oliguria, oligohidroamnios.
- **Feto receptor:** Hipervolemia, poliuria, polihidroamnios.
- Ocurre en alrededor de 10-15% de los embarazos monocoriales.
- Los embarazos monocoriales tienen un riesgo aumentado de cardiopatías congénitas en comparación con embarazos bicoriales y embarazos únicos. Este riesgo es mayor en presencia de STFF.

Introducción


A



B



C



D





Figure 2. Risk of CHDs in MC twins with and without TTTS. (A) MC twins vs. singletons, (B) MC twins with TTTS vs. singletons, (C) MC twins without TTTS vs. singletons, (D) MC twins with TTTS vs. MC twins without TTTS. Risk ratios with 95% confidence intervals (CIs) were calculated by a fixed effect model. The pooled risk ratio is represented by a black diamond, where diamond width corresponds to 95% CI bounds.

Epidemiología

Prevalencia de cardiopatías congénitas en embarazos monocoriales

- VSD 25.9/1000
 - RVOTO 22.3/1000
 - ASD 13.6/1000
 - CoA 2.1/1000
 - AS 2.6/1000
 - TOF 0.9/1000
 - TGA 0.9/1000
- En STFF existe un RR de 70 (95% IC: 27-179, p<0.001) para RVOTO (35/1000 vs 0.5/1000 en embarazos únicos)

Fisiopatología



Mahieu-Caputo D, Meulemans A, Martinovic J, Gubler MC, Delezoide AL, Muller F, Madelenat P, Fisk NM, Dommergues M. Paradoxic activation of the renin-angiotensin system in twin-twin transfusion syndrome: an explanation for cardiovascular disturbances in the recipient. *Pediatr Res.* 2005 Oct;58(4):685-8.

Fisiopatología




Fig. 1. Pathogenesis of severe TTTS: involvement of the RAS. ATII = Angiotensin II; NF = natriuretic factor.

Mahieu-Caputo D, Muller F, Joly D, Gubler MC, Lebidois J, Fermont L, Dumez Y, Dommergues M. Pathogenesis of twin-twin transfusion syndrome: the renin-angiotensin system hypothesis. *Fetal Diagn Ther*. 2001 Jul-Aug;16(4):241-4.

Fisiopatología




Figure 1. Endothelin (ET-1) concentrations in monochorionic twins with or without twin-twin transfusion syndrome (TTTS) **(a)** at the time of fetal blood sampling *in utero*; **(b)** in amniotic fluid, and **(c)** in umbilical vein (V) and artery (A) at the time of delivery. NS = non-significant.

Fisiopatología




Fig 1. Comparison of fetal brain natriuretic peptide (BNP) levels in utero between (A) recipient and donor twins with chronic twin-twin transfusion syndrome (TTTS) and (B) monochorionic twin pairs without chronic TTTS. C and D compare fetal atrial natriuretic peptide (ANP) levels in utero between twin pairs with and without chronic TTTS, respectively.

Fisiopatología




Figure 3 Proposed pathophysiology of recipient twin in twin–twin transfusion syndrome. (1) Neuroendocrine factors cause increased recipient blood pressure. (2) Decreased right-to-left shunting and altered ductus venosus (DV) filling times are observed. (3) Altered left ventricular (LV) function and, ultimately, (4) bilateral atrioventricular valve regurgitation and ventricular hypertrophy are seen. Ao, aorta; DA, ductus arteriosus; FO, foramen ovale; LA, left atrium; PA, pulmonary arteries; PV, pulmonary veins; RA, right atrium; RV, right ventricle; SVC, superior vena cava; UA, umbilical artery; UV, umbilical vein.

- 1.- Factores neuroendocrinos aumentan presión arterial en el receptor.
- 2.- Disminuye el shunt derecha-izquierda y se altera el ductus venoso.
- 3.- Se altera la función del ventrículo izquierdo
- 4.- Regurgitación en ambas válvulas AV e hipertrofia ventricular

Clasificación STFF

TABLE 1

Quintero Staging of TTS is the Established Framework for Staging TTS

| | |
|-----------|---|
| Stage I | Donor bladder visible |
| Stage II | No donor bladder Normal Doppler assessments |
| Stage III | Abnormal Doppler assessments For donor: -AEDF/REDF in donor umbilical artery +/- For recipient: -Abnormal DV flow -Pulsatile umbilical vein |
| Stage IV | Hydrops in one twin |
| Stage V | Death of one/both twins |

Note: AEDF; absent end diastolic flow; REDF: reversed end diastolic flow;
DV: ductus venosus.

TABLE 2

Quantifiable Functional Changes in the Recipient Twin

| | | |
|---|-------------------------------------|--|
| 1 | Ventricular myocardial hypertrophy | <ul style="list-style-type: none"> • Right ventricle before left • Both ventricles in time |
| 2 | Increased heart size | <ul style="list-style-type: none"> • Hypertrophy not dilatation • Increased C:T ratio |
| 3 | Ventricular hypokinesia | <ul style="list-style-type: none"> • Increased MPI |
| 4 | Atrioventricular valvar dysfunction | <ul style="list-style-type: none"> • Regurgitation • TV before MV • Monophasic inflow |
| 5 | +/- RVOTO | <ul style="list-style-type: none"> • Acceleration across the RVOT • Pulmonary regurgitation |

Note: C:T ratio = cardiothoracic; TV = tricuspid valve; MV = mitral valve;
RVOT = Right ventricular outflow tract.

TABLE 4

Possible Mechanisms for the Development of Acquired Structural Heart Disease

| | Right ventricular outflow tract obstruction in recipient | Coarctation of the aorta in the donor |
|--|---|--|
| | Right ventricular (RV) myocardial hypertrophy | High placental resistance |
| | Reduced RV function + high systemic pressures | + Hypovolaemia |
| | +/- Severe tricuspid regurgitation | Decreased venous return from placenta → Reduced anterograde flow from left ventricle across aortic isthmus |
| | Inability of the RV to generate enough pressure to open pulmonary valve | Reduced growth of arch |
| | Progression to muscular (subvalvar) and valvar RVOTO | Evolving coarctation |

Cardiopatía en STFF

American Journal of Obstetrics and Gynecology (2005) 192, 892–902



ELSEVIER

American Journal of
OBSTETRICS and
GYNECOLOGY
www.ajog.org

Prenatal cardiovascular manifestations in the twin-to-twin transfusion syndrome recipients and the impact of therapeutic amnioreduction

Catherine Barrea, MD,^a Fawaz Alkazaleh, MD,^b Greg Ryan, MB,^b
 Brian W. McCrindle, MD,^a Anita Roberts, BSc,^a Jean-Luc Bigras, MD,^a
 Jon Barrett, MD,^c Gareth P. Seaward, MB,^b Jeffrey F. Smallhorn, MB, BS,^a
 Lisa K. Hornberger, MD^{a,*}

Department of Pediatrics, Division of Cardiology, Fetal Cardiac Program, The Hospital for Sick Children,^a and the
 Division of Maternal-Fetal Medicine, Mount Sinai Hospital^b and Women's College Hospital,^c University of Toronto,
 Ontario, Canada

Table II Diastolic dysfunction in the recipient twin at examination (n = 28 recipients)

| Variable | Proportion (n/N) |
|---|------------------|
| Diastolic dysfunction | 16/24 (67%) |
| Abnormal IVC/hepatic vein blood flow | 13/20 (65%) |
| Abnormal ductus venosus blood flow | 7/14 (50%) |
| Umbilical vein pulsations | 9/22 (41%) |
| Abnormal mitral valve blood inflow | 8/21 (38%) |
| Abnormal tricuspid valve blood inflow | 12/20 (60%) |
| Abnormal LV isovolumic contraction time | 11/18 (61%) |

Barrea C, Alkazaleh F, Ryan G, McCrindle BW, Roberts A, Bigras JL, Barrett J, Seaward GP, Smallhorn JF, Hornberger LK. Prenatal cardiovascular manifestations in the twin-to-twin transfusion syndrome recipients and the impact of therapeutic amnioreduction. Am J Obstet Gynecol. 2005 Mar;192(3):892-902.

Cardiopatía en STFF

Table III The cardiovascular findings at examination, according to the staging of Quintero et al²²

| Finding | Stage | | | <i>P</i> value |
|--|--------------|--------------|--------------|----------------|
| | I-II | III | IV | |
| Total recipients (n) | 7 | 17 | 4 | |
| RVSF (%) [*] | 30 ± 9 | 33 ± 13 | 21 ± 8 | NS |
| RVSF <28% (n/N) | 1/7 (14%) | 5/15 (33%) | 3/4 (75%) | NS |
| LVSF (%) [*] | 40 ± 11 | 39 ± 10 | 28 ± 5 | NS |
| LVSF <28% (n/N) | 0/7 (0%) | 2/16 (13%) | 2/4 (50%) | NS |
| Moderate to severe tricuspid valve regurgitation (n/N) | 0/5 (0%) | 3/17 (18%) | 4/4 (100%) | .004 |
| Moderate to severe mitral valve regurgitation (n/N) | 0/5 (0%) | 0/17 (0%) | 3/4 (75%) | .002 |
| Diastolic dysfunction (n/N) | 3/6 (50%) | 9/14 (64%) | 4/4 (100%) | NS |
| RV anterior wall thickness (Z score) [*] | +1.46 ± 1.39 | +1.98 ± 1.53 | +3.43 ± 1.54 | NS |
| Interventricular wall thickness (Z score) [*] | +1.70 ± 0.87 | +2.20 ± 1.22 | +2.52 ± 0.53 | NS |
| LV posterior wall thickness (Z score) [*] | +1.67 ± 1.53 | +1.74 ± 1.59 | +3.31 ± 0.60 | NS |
| Right and/or left hypertrophy (n/N) | 2/7 (29%) | 9/15 (60%) | 4/4 (100%) | .077 |

NS, Not statistically significant (*P* ≥ 1.0).

* Data are given as mean ± SD.

Cardiopatía en STFF




Figure 3 The progression of right ventricular hypertrophy (RVAW thickness normalized for GA and expressed in Z score) in fetuses that were assessed serially after amnioreductions. **A**, Graph shows a regression curve for all measures; **B**, graph shows individual measurements for each fetus that was assessed. Similar progression was observed for the interventricular septum and the left ventricular posterior wall (results not shown).




Figure 4 The changes in RVSF (**A**) and LVSF (**B**) between the first and the last postamnioreduction echocardiogram, respectively, that was performed in 19 recipients. RV systolic function remained (10/19) or became (5/19) abnormal (SF, <28%) in 79% and normalized in only 1 recipient, despite amnioreduction, whereas LV systolic function remained (13/19) or became (1/19) normal (SF, $\geq 28\%$) in 74% and became abnormal (SF, <28%) in 3 cases.

Cardiopatía en STFF

American Journal of Obstetrics and Gynecology (2006) 195, 1388–95



American Journal of
**Obstetrics &
Gynecology**
www.ajog.org

Impact of selective laser ablation of placental anastomoses on the cardiovascular pathology of the recipient twin in severe twin-twin transfusion syndrome

Catherine Barrea, MD,^{a,†} Lisa K. Hornberger, MD,^{a,*†} Fawaz Alkazaleh, MD,^{b,†} Brian W. McCrindle, MD,^a Anita Roberts, BSc, RDGS,^a Olena Berezovska, MD,^a Rory Windrim, MB,^b P. Gareth Seaward, MB, BCh,^b Jeffrey F. Smallhorn, MB, BS,^a Greg Ryan, MB^b

Department of Pediatrics, Division of Cardiology, Fetal Cardiac Program, The Hospital for Sick Children,^a University of Toronto; Fetal Medicine Unit, Department of Obstetrics & Gynaecology, Mount Sinai Hospital; University of Toronto, Ontario, Canada^b

Table I Demographic data for the 35 pregnancies assessed by fetal echocardiography

| | Subgroup with echo pre and post (n = 22) | Subgroup with echo pre only (n = 13) | P value |
|-----------------------------------|--|--------------------------------------|---------|
| Maternal age (years) | 31 ± 5 | 29 ± 5 | NS |
| GA at presentation (weeks) | 19.4 ± 2.8 | 19.2 ± 2.2 | NS |
| GA at laser (weeks) | 21.7 ± 2.6 | 21.3 ± 2.8 | NS |
| Number of anastomoses ablated | 10 ± 3 | 11 ± 5 | NS |
| Volume of amnioreduction (liters) | 2.3 ± 1.4 | 2.1 ± 0.8 | NS |
| GA at delivery (weeks) | 31.9 ± 4.5 | 28.9 ± 6.6 | NS |
| TTTS stage: | | | |
| Stage 1 | 0 | 1 | |
| Stage 2 | 1 | 3 | |
| Stage 3 | 16 | 8 | |
| Stage 4 | 5 | 1 | |

Demographic data, laser procedure characteristics, and GA at delivery expressed as mean ± SD. Comparisons were made between the two subgroups with an unpaired student's *t* test. GA, Gestational age.

Cardiopatía en STFF

Table II Cardiovascular findings among recipient twins before and acutely after the laser procedure

| | n | Pre-laser | Post-laser | P value |
|------------------------------|----|--------------|--------------|---------|
| Gestational age (weeks) | 22 | 21.4 ± 2.7 | 22.4 ± 2.4 | NS |
| Fetal heart rate (bpm) | 16 | 144 ± 9 | 143 ± 5 | NS |
| Cardiothoracic ratio | 18 | 0.50 ± 0.09 | 0.51 ± 0.11 | NS |
| Z score RVED | 21 | -0.70 ± 1.00 | -0.57 ± 0.68 | NS |
| Z score LVED | 21 | -0.58 ± 0.77 | -0.54 ± 0.77 | NS |
| Z score LVPW | 18 | +2.09 ± 1.98 | +1.68 ± 1.75 | NS |
| Z score RVAW | 18 | +1.83 ± 1.95 | +1.84 ± 1.64 | NS |
| Z score IVS | 17 | +2.16 ± 1.64 | +2.16 ± 1.26 | NS |
| <i>Systolic function</i> | | | | |
| RVSF (%) | 22 | 25 ± 12 | 32 ± 9 | 0.007 |
| LVSF (%) | 22 | 32 ± 9 | 36 ± 7 | 0.04 |
| RVSF < 28% | 22 | 13 (59%) | 8 (36%) | < 0.03 |
| LVSF < 28% | 22 | 6 (27%) | 2 (9%) | 0.1 |
| Moderate to severe TR | 22 | 9 (41%) | 4 (18%) | 0.03 |
| Moderate to severe MR | 22 | 6 (27%) | 3 (14%) | NS |
| <i>Diastolic dysfunction</i> | | | | |
| (≥ 2 abnormal parameters) | 22 | 16 (73%) | 11 (50%) | 0.06 |
| Abnormal IVC flow | 20 | 14 (70%) | 14 (70%) | NS |
| Abnormal DV flow | 16 | 13 (81%) | 9 (56%) | < 0.05 |
| UV pulsations | 18 | 16 (89%) | 9 (50%) | 0.008 |
| Abnormal LV IVRT | 17 | 9 (53%) | 6 (35%) | NS |
| LV IVRT (msec) | 17 | 58 ± 9 | 54 ± 8 | 0.048 |
| Abnormal TV flow | 13 | 11 (85%) | 3 (23%) | 0.005 |
| Abnormal MV flow | 16 | 6 (38%) | 1 (6%) | 0.06 |
| RV Tei ratio | 10 | 1.41 ± 0.34 | 1.00 ± 0.22 | 0.03 |
| LV Tei ratio | 17 | 0.99 ± 0.33 | 0.90 ± 0.24 | NS |

The results are expressed as mean ± SD or the absolute number with percentage in paren. The Tei index is expressed as a ratio of the actual value divided by the normal value for gestational age, as such a perfectly normal value = 1. Statistical analyses were done by paired student's t test for continuous variables and by McNemar test for proportions. bpm, Beats per minute; DV, ductus venosus; IVC, inferior vena cava; IVS, interventricular septum thickness; LVED, left ventricular end-diastolic diameter; LV IVRT, left ventricular isovolumic relaxation time in milliseconds; LVPW, left ventricular posterior wall thickness; LVSF, left ventricular shortening fraction; MV, mitral valve; MR, mitral regurgitation; RVAW, right ventricular anterior wall thickness; RVED, right ventricular end-diastolic diameter; RVSF, right ventricular shortening fraction; TV, tricuspid valve; TR, tricuspid regurgitation.

Cardiopatía en STFF




Figure 1 This graph demonstrates the changes in **A**, right (RV) and **B**, left ventricular (LV) shortening fraction (SF) immediately before and after laser.




Figure 3 This graph shows the evolution of right ventricular anterior wall thickness (RVAW) Z score just before the laser (PRE), at the first echo after the procedure (POST1), and at late follow-up (POST2). There was no progression of wall thickness after the laser except for one case in which there was evidence of ongoing twin-twin transfusion syndrome despite ablation of multiple anastomoses. Similar observations were made for the interventricular septum and LV posterior wall thickness (results not shown).



SMFM MEETING PAPERS

www.AJOG.org

The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease

Jack Rychik, MD; Zhiyun Tian, MD; Michael Bebbington, MD; Feng Xu, MD; Margaret McCann, BA; Stephanie Mann, MD; R. Douglas Wilson, MD; Mark P. Johnson, MD

Rychik J, Tian Z, Bebbington M, Xu F, McCann M, Mann S, Wilson RD, Johnson MP. The twin-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. Am J Obstet Gynecol. 2007 Oct;197(4):392.e1-8.

Cardiopatía en STFF

TABLE 1

Cardiovascular parameters that were used to make up the CV Score and the number of fetuses with specific cardiovascular findings


| Variable | Parameter | Finding | Numeric score | Fetuses with this finding (n) |
|-----------|-------------------------------|--------------------------------------|---------------|-------------------------------|
| Donor | Umbilical artery | Normal | 0 | 96 (64%) |
| | | Decreased diastolic blood flow | 1 | 34 (23%) |
| | | Absent/reversed diastolic blood flow | 2 | 20 (13%) |
| Recipient | Ventricular hypertrophy | None | 0 | 77 (51%) |
| | | Present | 1 | 73 (49%) |
| Recipient | Cardiac dilation | None | 0 | 78 (52%) |
| | | Mild | 1 | 47 (31%) |
| | | >mild | 2 | 25 (17%) |
| Recipient | Ventricular dysfunction | None | 0 | 117 (78%) |
| | | Mild | 1 | 12 (8%) |
| | | >mild | 2 | 21 (14%) |
| Recipient | Tricuspid valve regurgitation | None | 0 | 97 (65%) |
| | | Mild | 1 | 31 (21%) |
| | | >mild | 2 | 22 (15%) |
| Recipient | Mitral valve regurgitation | None | 0 | 131 (87%) |
| | | Mild | 1 | 6 (4%) |
| | | >mild | 2 | 13 (9%) |
| Recipient | Tricuspid valve inflow | Double-peak | 0 | 113 (75%) |
| | | Single-peak | 1 | 37 (25%) |
| Recipient | Mitral valve inflow | Double-peak | 0 | 135 (90%) |
| | | Single-peak | 1 | 15 (10%) |
| Recipient | Ductus venosus | All antegrade | 0 | 114 (76%) |
| | | Absent diastolic blood flow | 1 | 13 (9%) |
| | | Reverse diastolic blood flow | 2 | 23 (15%) |
| Recipient | Umbilical vein | No pulsations | 0 | 136 (91%) |
| | | Pulsations | 1 | 14 (9%) |
| Recipient | Right-sided outflow tract | Pulmonary artery > aorta | 0 | 126 (84%) |
| | | Pulmonary artery = aorta | 1 | 13 (9%) |
| | | Pulmonary artery < aorta | 2 | 8 (5%) |
| | | Right ventricle outflow obstruction | 3 | 3 (2%) |
| Recipient | Pulmonary regurgitation | None | 0 | 145 (97%) |
| | | Present | 1 | 5 (3%) |

CV 1 0-5
 CV 2 6-10
 CV 3 11-15
 CV 4 16-20

Cardiopatía en STFF

FIGURE 1

Doppler spectral display of umbilical arterial and venous flow in the donor (top panel) and recipient (bottom panel) twins




Arrows point to the reversal of diastolic blood flow that was noted in the donor twin as arterial blood flow below the baseline. Umbilical venous blood flow is continuous and nonphasic, all below the baseline.

Rychik. The twin-to-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. AJOG 2007.

FIGURE 2

Severe tricuspid and mitral regurgitation in a recipient twin heart




Top panels are the 2-dimensional images of a 4-chamber view; bottom panels are the color Doppler images that show valve regurgitation. The right-side panels show tracings of the area of right atrium (*top*) and the area of the color regurgitant jet (*bottom*). Note that the color jet regurgitant area is much >25% of the right atrial area, which designates this as hemodynamically significant (more than mild) tricuspid regurgitation.

Rychik. The twin-to-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. AJOG 2007.

FIGURE 3

Doppler spectral display of inflow pattern across the tricuspid valve

A



B






FIGURE 4

Doppler spectral display of flow in the ductus venosus

Donor



Recipient



Cardiopatía en STFF


TABLE 4

Quantitative parameters of cardiovascular function evaluated in both the donor and recipient fetuses

| Parameter | Donor | Recipient | P value |
|--|-------------|-------------|---------|
| Weight (g) | 399 (235) | 527 (285) | <.0001 |
| Umbilical artery | | | |
| S wave peak velocity (cm/s) | 29.2 (8.7) | 41.7 (12.9) | <.0001 |
| D wave peak velocity (cm/s) | 4.7 (4.3) | 9.7 (4.5) | <.0001 |
| Pulsatility index | 1.81 (0.8) | 1.46 (0.4) | <.0001 |
| Middle cerebral artery | | | |
| S wave peak velocity (cm/s) | 27.3 (8.1) | 26.2 (8) | NS |
| D wave peak velocity (cm/s) | 5.1 (2.6) | 5.1 (2.1) | NS |
| Pulsatility index | 1.79 (0.4) | 1.70 (0.4) | NS |
| Ductus venosus | | | |
| A wave peak velocity (cm/s) | 18.5 (6.8) | 13.3 (16.7) | <.01 |
| S wave peak velocity (cm/s) | 51.1 (13) | 53.3 (13.6) | NS |
| A/S ratio | 0.38 (0.12) | 0.24 (0.31) | <.001 |
| Tricuspid valve closure-to-opening time (msec) | 232 (18) | 275 (32) | <.0001 |
| Pulmonary artery ejection time (msec) | 169 (13) | 169 (21) | NS |
| Right ventricle myocardial performance index (Tei Index) | 0.38 (0.11) | 0.69 (0.47) | <.0001 |
| Mitral valve closure-to-opening time (msec) | 222 (19) | 263 (29) | <.0001 |
| Aorta ejection time (msec) | 166 (15) | 170 (17) | .07 |
| Left ventricle myocardial performance index (Tei Index) | 0.34 (0.12) | 0.59 (0.28) | <.0001 |

FIGURE 6

Bar graph shows the percentage of twin pairs with a particular cardiovascular grade for each Quintero stage



Note the presence of significant discrepancy in categorization of severity in particular for Quintero stages II and III, in which a wide variety of cardiovascular grades are found.

Rychik. The twin-to-twin transfusion syndrome: spectrum of cardiovascular abnormality and development of a cardiovascular score to assess severity of disease. AJOG 2007.

Cardiopatía en STFF

Ultrasound Obstet Gynecol 2018; 51: 341–348
 Published online 8 February 2018 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.17480

Cardiac pathophysiology in twin–twin transfusion syndrome: new insights into its evolution

C. WOHLMUTH^{1,2} , D. BOUDREAUX¹, K. J. MOISE Jr¹, A. JOHNSON¹, R. PAPANNA¹, M. BEBBINGTON¹ and H. M. GARDINER¹

¹The Fetal Center, Children's Memorial Hermann Hospital and the Department of Obstetrics, Gynecology and Reproductive Science, UTHHealth McGovern Medical School, Houston, TX, USA; ²Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria

Table 3 Calculated cardiac output in 26 uncomplicated monochorionic–diamniotic (MCDA) pregnancies and 119 pregnancies complicated by Stages I and II or Stages III and IV twin–twin transfusion syndrome (TTTS)

| Parameter | Uncomplicated (n = 26) | | | TTTS I+II (n = 61) | | | TTTS III+IV (n = 58) | | |
|------------------------------------|------------------------|--------------|-------|--------------------|-----------|-------|----------------------|-----------|-------|
| | Larger twin | Smaller twin | P | Recipient | Donor | P | Recipient | Donor | P |
| Left cardiac output (mL/min/kg) | 209 ± 129 | 158 ± 51 | 0.091 | 168 ± 49 | 157 ± 64 | 0.205 | 190 ± 58 | 149 ± 61 | 0.001 |
| Right cardiac output (mL/min/kg) | 301 ± 225 | 259 ± 87 | 0.568 | 244 ± 74 | 233 ± 86 | 0.328 | 235 ± 119 | 233 ± 85 | 0.783 |
| Combined cardiac output (mLmin/kg) | 510 ± 260 | 417 ± 89 | 0.101 | 411 ± 95 | 376 ± 135 | 0.182 | 423 ± 140 | 381 ± 119 | 0.088 |

Data are given as mean ± SD of left, right and combined cardiac output, normalized to estimated fetal weight.

Table 2 Basic cardiovascular parameters in 26 uncomplicated monochorionic–diamniotic (MCDA) pregnancies and 119 pregnancies complicated by Stages I and II or Stages III and IV twin–twin transfusion syndrome (TTTS)

| Parameter | Uncomplicated MCDA (n=26) | TTTS I+II (n=61) | TTTS III+IV (n=58) |
|---------------------------------|------------------------------|---------------------|-----------------------|
| TTTS recipient/larger MCDA twin | | | |
| HR (bpm) | 145 ± 7 | 144 ± 7 | 142 ± 8 |
| TV E/A ratio | 0.64 ± 0.10 | 0.62 ± 0.12 | 0.65 ± 0.16 |
| TV E/A fusion | 4 (15.4) | 16 (26.2) | 20 (34.5) |
| Tricuspid regurgitation | 4 (15.4) | 14 (23.0) | 29 (50.0) |
| Mild | 4 (15.4) | 9 (14.8) | 12 (20.7) |
| Moderate–severe | — | 5 (8.2) | 17 (29.3) |
| MV E/A ratio | 0.64 ± 0.09 | 0.61 ± 0.10 | 0.60 ± 0.11 |
| MV E/A fusion | — | 5 (8.2) | 6 (10.3) |
| Mitral regurgitation | — | 3 (4.9) | 16 (27.6) |
| Mild | — | 1 (1.6) | 7 (12.1) |
| Moderate–severe | — | 2 (3.3) | 9 (15.5) |
| DA reverse flow | — | — | 5 (8.6) |
| UA-PI | 1.32 ± 0.19 | 1.34 ± 0.27 | 1.82 ± 0.97 |
| UA-AREDF | — | — | 6 (10.3) |
| DV-AREDF | — | — | 23 (39.7) |
| UV pulsations | — | — | 21 (36.2) |
| MCA-PSV MoM | 1.2 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 |
| TTTS donor/smaller MCDA twin | | | |
| HR (bpm) | 148 ± 9 | 147 ± 10 | 147 ± 10 |
| TV E/A ratio | 0.69 ± 0.07 | 0.67 ± 0.11 | 0.69 ± 0.10 |
| TV E/A fusion | — | — | — |
| Tricuspid regurgitation | — | 5 (8.2) | 2 (3.4) |
| Mild | — | 5 (8.2) | 2 (3.4) |
| Moderate–severe | — | — | — |
| MV E/A ratio | 0.71 ± 0.30 | 0.66 ± 0.13 | 0.67 ± 0.13 |
| MV E/A fusion | — | — | — |
| Mitral regurgitation | — | — | — |
| Mild | — | — | — |
| Moderate–severe | — | — | — |
| UA-PI | 1.33 ± 0.22 | 1.43 ± 0.34 | 1.94 ± 0.83 |
| UA-AREDF | — | — | 19 (32.8) |
| DV-AREDF | — | — | 9 (15.5) |
| UV pulsations | — | — | 9 (15.5) |
| MCA-PSV MoM | 1.1 ± 0.2 | 1.2 ± 0.3 | 1.3 ± 0.4 |

Data are given as mean ± SD or n (%). AREDF, absent or reversed end-diastolic flow; bpm, beats per minute; DA, ductus arteriosus; DV, ductus venosus; E/A, fusion of passive (E) and active (A) ventricular filling waves; HR, heart rate; MCA-PSV, middle cerebral artery peak systolic velocity; MoM, multiples of the median; MV, mitral valve; PI, pulsatility index; TV, tricuspid valve; UA, umbilical artery; UV, umbilical vein.




Figure 1 Box-and-whiskers plots comparing left (a) and right (b) myocardial performance index (MPI), left tissue Doppler-derived velocities during late diastole (A') (c) and systole (S') (d), right tissue Doppler velocity during early diastole (E') (e), transtricuspid-to-tricuspid annular velocity ratio (E/E') (f) and tricuspid annular plane systolic excursion (TAPSE) (g) of recipient cotwins, as well as right tissue Doppler-derived velocity during systole (S') of donor cotwins (h), in pregnancies complicated by Stages I and II (TTTS I+II) or Stages III and IV (TTTS III+IV) twin–twin transfusion syndrome and uncomplicated monochorionic–diamniotic (MCDA) pregnancies. Boxes show median and interquartile range, and whiskers are range.




Figure 2 Box-and-whiskers plots comparing left (a) and right (b) myocardial performance index (MPI), left (c) and right (d) tissue Doppler-derived velocities during systole (S') and mitral (MAPSE) (e) and tricuspid (TAPSE) (f) annular plane systolic excursion of recipient cotwin, as well as transmural-to-mitral annular velocity ratio (E/E') (g) and combined cardiac output (CCO) (h) of donor cotwin, in 41 pregnancies complicated by twin-twin transfusion syndrome, before and after selective fetoscopic laser photoocoagulation (SFLP). Boxes show median and interquartile range and whiskers are range. NS, not significant.

Cardiopatía en STFF

Feto donante

Journal of Paediatrics and
Child Health



doi:10.1111/j.1440-1754.2009.01641.x

ORIGINAL ARTICLE

Twin-twin transfusion syndrome, coarctation of the aorta and hypoplastic aortic arch: A case series report

Jutta van den Boom,¹ Malcolm Battin^{1,2} and Tim Hornung³

¹Newborn Service, Auckland City Hospital, ²Departments of Paediatrics and Obstetrics and Gynaecology, University of Auckland and ³Department of Paediatric Cardiology, Starship Hospital, Auckland, New Zealand

Table 1 Overview of demographics, main (cardiac) diagnoses and outcome of the twin pairs

| | Gender | Gestation (weeks) | Birthweight (g) | Diagnosis | Outcome |
|--------|--------|-------------------|-----------------|---|-----------------------------------|
| Twin 1 | Female | 27 | 1200 | PPHN | Death |
| Twin 2 | Female | 27 | 725 | PDA, coarctation | Persistent neurological problems |
| Twin 1 | Male | 28 | 1180 | CLD, PDA | Discharged |
| Twin 2 | Male | 28 | 850 | RDS, PDA, coarctation | Discharged |
| Twin 1 | Female | 25 | 713 | CLD, coarctation | Discharged |
| Twin 2 | Female | 25 | 937 | Dysplastic aortic valves, LV hypertrophy, severe MR | Death |
| Twin 1 | Male | 33 | 1520 | Coarctation, PDA, cystic PVL | Transferred to referring hospital |
| Twin 2 | Male | 33 | 2490 | PPHN, Ebstein's anomaly | Transferred to referring hospital |

CLD, chronic lung disease; LV, left ventricle; MR, mitral regurgitation; PDA, persistent ductus arteriosus; PPHN, persistent pulmonary hypertension of the newborn; PVL, periventricular leucomalacia; RDS, respiratory distress syndrome; VSD, ventricular septal defect.

Cardiopatía en STFF

Feto receptor

Right ventricular outflow tract obstruction (RVOTO)




Fig. 1. Echocardiographic diagnostic criteria. **a** PS (thickened or narrow pulmonary valve, turbulent flow, peak systolic velocity >120 cm/s). **b** PA (no forward flow across the pulmonary valve, reverse flow in the ductus arteriosus).

Ortiz JU, Masoller N, Gómez O, Bennasar M, Eixarch E, Lobmaier SM, Crispi F, Gratacos E, Martinez JM. Rate and Outcomes of Pulmonary Stenosis and Functional Pulmonary Atresia in Recipient Twins with Twin-Twin Transfusion Syndrome. *Fetal Diagn Ther*. 2017;41(3):191-196.

Cardiopatía en STFF

Feto receptor

Right ventricular outflow tract obstruction (RVOTO)

Outflow Tract Abnormalities in Twin-twin Transfusion

3

Table 2. Definitions of Anatomic Subtype and Post-SFLP Improvement in RVOT Abnormalities

| | Pulmonary Atresia | Pulmonary Stenosis | Isolated Pulmonary Insufficiency |
|-----------------------|--|---|--|
| Anatomic findings | Functional: none–minimal antegrade flow across RVOT, PI present, exclusive retrograde flow in DA Anatomic: no antegrade flow across RVOT, no PI present | Turbulent, accelerated flow across anatomically thickened/dysplastic pulmonary valve or narrowed RVOT | Pulmonary insufficiency in absence of RVOT obstruction |
| Post-SFLP improvement | Appearance of improved antegrade flow across RVOT and/or: Change to normal antegrade flow across DA | 20% decrement in flow velocity across RVOT | Resolution of pulmonary insufficiency |

DA, ductus arteriosus; PI, pulmonary insufficiency; RVOT, right ventricular outflow tract; SFLP, selective fetoscopic laser procedure.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. Congenit Heart Dis. 2015 May-Jun;10(3):209-18.

Cardiopatía en STFF

Feto receptor

Table 4. Published Reports on the *Prenatal* Prevalence of RVOT Abnormalities in Twin–twin Transfusion Syndrome

| Author | Year | Subjects (n) | Prevalence of RVOT Abnormality (%) |
|-----------------------------------|------|--------------|------------------------------------|
| Lougheed et al. ⁹ | 2001 | 48 | 6/48 (12.5) |
| Barrea et al. ¹⁰ | 2005 | 28 | 4/28 (14.3) |
| Michelfelder et al. ¹¹ | 2007 | 42 | 5/42 (11.9) |
| Moon-Grady et al. ¹⁵ | 2011 | 76 | 16/76 (21.0) |
| Current study | N/A | 610 | 53/610 (8.7) |

RVOT, right ventricular outflow tract.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. Congenit Heart Dis. 2015 May-Jun;10(3):209-18.

Cardiopatía en STFF

Feto receptor

Table 3. Echocardiographic Findings in Three Subgroups with Right Ventricular Outflow Tract Abnormalities in Recipient Twins

| | | PA (n = 24) | PS (n = 16) | PI (n = 13) | P Value |
|---------------|--------------------------|----------------|----------------|----------------|---------|
| General | GA at evaluation (wk) | 20.9 ± 2.4 | 19.9 ± 1.9 | 21.7 ± 3.4 | NS |
| | Quintero Stage | 0/24 (0) | 3/16 (19) | 0/13 (0) | .0006 |
| | II | 10/24 (42) | 12/16 (75) | 11/13 (85) | |
| | III | 14/24 (58) | 1/16 (6) | 2/13 (15) | |
| | IV | | | | |
| | CT ratio | 0.45 ± 0.06* | 0.41 ± 0.05 | 0.36 ± 0.06 | .001 |
| | DA retrograde flow | 22/22 (100) | 4/15 (27) | 1/11 (9) | <.0001 |
| | Hydrops | 14/24 (58) | 1/16 (6) | 2/13 (15) | .0008 |
| Function | ≥Moderate RV dysfunction | 22/23 (96) | 4/16 (25) | 8/13 (62) | <.0001 |
| | ≥Moderate TR | 22/24 (92) | 12/16 (75) | 6/13 (46) | .009 |
| | DV flow reversal | 21/24 (88) | 6/15 (40) | 8/13 (62) | .008 |
| | UV pulsation | 10/24 (42) | 3/15 (20) | 2/13 (15) | NS |
| RV morphology | ≥Moderate RV hypertrophy | 17/22 (77) | 9/16 (56) | 6/13 (46) | NS |
| | RV hypoplasia | 3/24 (13) | 0/16 (0) | 0/13 (0) | NS |
| | Z _{RVEDD} | 0.7 ± 1.6 | -0.4 ± 1.2 | 0.5 ± 1.2 | NS |
| | Z _{TV} | -0.7 ± 1.3 | -1.4 ± 1.4 | -0.7 ± 1.3 | NS |
| | Z _{PV} | -0.6 ± 1.3 | -1.3 ± 1.5* | 0.7 ± 0.8 | .03 |
| | Z _{MPA} | 0.0 ± 0.9 | 1.5 ± 1.3† | 0.4 ± 0.8 | .009 |

Data are presented as mean ± standard deviation or frequency/total observations (%). For denominators <total number in each group, data were not available for all subjects. For intergroup comparisons (ANOVA with Bonferroni correction): *P < .05 vs. PI; †P < .05 vs. PA.

ANOVA, analysis of variance; CT, cardiothoracic; DA, ductus arteriosus; DV, ductus venosus; GA, gestational age; MPA, main pulmonary artery; NS, not statistically significant; PA, pulmonary atresia; PI, isolated pulmonary insufficiency; PS, pulmonary stenosis; PV, pulmonary valve annulus; RV, right ventricle; RVEDD, right ventricular end-diastolic dimension; TR, tricuspid regurgitation; TV, tricuspid valve annulus; UV, umbilical vein.

Cardiopatía en STFF

Feto receptor




Figure 1. Study population with distribution of right ventricular outflow tract (RVOT) abnormalities by type. PA, pulmonary atresia; PS, pulmonary stenosis; TTS, twin–twin transfusion syndrome.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. *Congenit Heart Dis.* 2015 May-Jun;10(3):209-18.

Cardiopatía en STFF

Feto receptor




Figure 3. Postnatal cardiac outcomes in recipient twins with pulmonary atresia (PA). IUFD, intrauterine fetal demise; LTFU, lost to follow-up; RVOT, right ventricular outflow tract.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. Congenit Heart Dis. 2015 May-Jun;10(3):209-18.

Cardiopatía en STFF

Feto receptor




Figure 4. Postnatal cardiac outcomes in recipient twins with pulmonary stenosis (PS). IUFD, intrauterine fetal demise; LTFU, lost to follow-up.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. Congenit Heart Dis. 2015 May-Jun;10(3):209-18.

Cardiopatía en STFF

Feto receptor




Figure 5. Postnatal cardiac outcomes in recipient twins with isolated pulmonary insufficiency (PI). IUFD, intrauterine fetal demise; LTFU, lost to follow-up; RVOT, right ventricular outflow tract.

Michelfelder E, Tan X, Cnota J, Divanovic A, Statile C, Lim FY, Crombleholme T. Prevalence, Spectrum, and Outcome of Right Ventricular Outflow Tract Abnormalities in Twin-twin Transfusion Syndrome: A Large, Single-center Experience. Congenit Heart Dis. 2015 May-Jun;10(3):209-18.



Cardiopatía en STFF

Feto receptor

Right ventricular outflow tract obstruction (RVOTO)

Table 2 Pulmonary valve findings prior to selective fetoscopic laser photocoagulation (SFLP) and at follow-up (postnatal or autopsy)

| Case | Prenatal echo findings | GA at SFLP (weeks) | GA at delivery (weeks) | BW (g) | Postnatal findings (echo'autopsy) | Postnatal course |
|------|--|--------------------|------------------------|--------|-----------------------------------|--|
| 2 | PI, dysplasia without turbulence by color Doppler, ductal flow reversal | 23 + 5 | IUFD | — | Normal PV at autopsy | |
| 3 | PI, dysplasia with turbulence, 1.9 m/s peak systolic gradient | 23 + 3 | 28 + 2 | 870 | Valvar pulmonary stenosis | Balloon pulmonary valvuloplasty at 10 weeks |
| 4 | PI developed after SFLP (reversal of TTTS), no turbulence | 18 + 5 | TOP 23 + 4 | — | Normal PV at autopsy | |
| 7 | Normal initially, PI developed prior to SFLP, no turbulence or systolic gradient | 22 + 4 | 34 | 2060 | Normal | |
| 10 | PI, dysplasia, ductal flow reversal, no turbulence or systolic gradient | 19 + 6 | 38 + 3 | 3060 | Valvar pulmonary stenosis | Balloon pulmonary valvuloplasty at 3 months |
| 11 | PI only, no turbulence or systolic gradient | 20 + 4 | 38 | 2640 | Normal | |
| 14 | PI, no turbulence or systolic gradient | 21 + 1 | 26 | 878 | ASD, PDA | No cardiac intervention |
| 16 | PI, dysplasia, no turbulence or systolic gradient, intermittent ductal flow reversal | 24 | 29 + 2 | 1737 | Normal | RV function and TR improved after birth, normal at 1 month |

ASD, atrial septal defect; BW, birth weight; GA, gestational age; IUFD, intrauterine fetal death; PDA, patent ductus arteriosus; PI, pulmonary insufficiency; PV, pulmonary valve; RV, right ventricle; TOP, termination of pregnancy; TR, tricuspid regurgitation; TTTS, twin-twin transfusion syndrome.

Ultrasound Obstet Gynecol 2011; 37: 27–33
Published online 14 July 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.7748

Effect of selective fetoscopic laser photocoagulation therapy for twin-twin transfusion syndrome on pulmonary valve pathology in recipient twins

A. J. MOON-GRADY*†‡, L. RAND‡§, B. LEMLEY*, K. GOSNELL*†, L. K. HORNBERGER¶ and H. LEE**

*Pediatric Cardiology, University of California San Francisco, San Francisco, CA, USA; †Fetal Cardiovascular Program, University of California San Francisco, San Francisco, CA, USA; ‡Fetal Treatment Center, University of California San Francisco, San Francisco, CA, USA; §Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, CA, USA; ¶Pediatric Cardiology, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada; **Department of Pediatric Surgery, University of California San Francisco, San Francisco, CA, USA

Cardiopatía en STFF

Feto receptor

**Fetal Diagnosis
and Therapy**

Original Paper

Fetal Diagn Ther
DOI: 10.1159/000448075

Received: December 23, 2015
Accepted after revision: June 27, 2016
Published online: July 26, 2016

Rate and Outcomes of Pulmonary Stenosis and Functional Pulmonary Atresia in Recipient Twins with Twin-Twin Transfusion Syndrome

Javier U. Ortiz^{a, b, c} Narcis Masoller^{a, b} Olga Gómez^{a, b} Mar Bennasar^{a, b}
Elisenda Eixarch^{a, b} Silvia M. Lobmaier^{a, b, c} Fátima Crispí^{a, b} Eduard Gratacos^{a, b}
Josep María Martínez^{a, b}

^aBCNatal – Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), IDIBAPS, University of Barcelona, and ^bCenter for Biomedical Research on Rare Diseases (CIBER-EI), Barcelona, Spain;
^cFrauenklinik und Poliklinik, Technische Universität München, Munich, Germany

Table 1. Baseline characteristics and outcomes in the study groups

| | No PS/PA (n = 232) | PS/PA (n = 28) | p value |
|---|-----------------------|-------------------|--------------------|
| Maternal age, years | 32.5 (29–35) | 32.5 (28.3–35.9) | 0.891 ^a |
| Quintero stages III–IV | 101 (43.5%) | 25 (89.3%) | <0.001 |
| DV RF | 44 (19.0%) | 14 (50.0%) | <0.001 |
| TR | 38 (16.4%) | 17 (60.7%) | <0.001 |
| GA at surgery, weeks | 19.6 (17.4–21.8) | 19.5 (17.1–23.5) | 0.713 ^a |
| Miscarriage | 22 (9.5%) | 3 (10.7%) | 0.742 ^b |
| Preterm premature rupture of membranes <32 weeks ^c | 49 (21.1%) | 8 (28.6%) | 0.370 |
| Preterm delivery <32 weeks ^c | 79 (34.1%) | 13 (46.4%) | 0.253 |
| GA at delivery, weeks ^c | 34.2 (31.0–36.6) | 32.1 (27.5–36.0) | 0.074 |
| Survival of at least one twin at 6 months of age | 194 (83.6%) | 19 (67.9%) | 0.045 |
| Overall survival at 6 months of age | 338/464 (72.8%) | 32/56 (57.1%) | 0.015 |

Data are given as median (interquartile range) or n (%).

^aMann-Whitney U test. ^bFisher's exact test. ^cExcluded miscarriage.

Cardiopatía en STFF

Feto receptor

Table 2. Ultrasound findings, pregnancy outcomes and postnatal cardiologic follow-up data of surviving recipient twins with PS/PA prior to fetal surgery

| Case No. | Prenatal diagnosis | TTTS stage | GA at diagnosis, weeks | GA at delivery, weeks | Type of birth | Birth weight, g | Postnatal diagnosis | Postnatal intervention | Echocardiography at 6 months |
|----------|--------------------|------------|------------------------|-----------------------|---------------|-----------------|---------------------|---|------------------------------|
| 1 | PA | III | 22.4 | 36.0 | vaginal | 2,500 | normal | no | – |
| 2 | PA | III | 27.2 | 34.2 | CS | 2,140 | normal | no | – |
| 5 | PS | I | 21.0 | 34.6 | vaginal | 2,190 | severe PS | valvotomy at 15 days after PBPV failure at 6 days | severe PS |
| 8 | PS | III | 21.2 | 33.0 | CS | 1,860 | PA, hypoplastic RV | univentricular staged surgery at 15 days | exitus after surgery |
| 9 | PS | III | 19.0 | 33.0 | CS | 2,040 | normal | no | – |
| 10 | PA | IV | 23.3 | 36.2 | CS | 2,340 | normal | no | – |
| 11 | PS | III | 19.2 | 32.5 | CS | 2,160 | severe PS | PBPV at 10 days and 6 months | severe PS |
| 13 | PS | II | 20.0 | 30.0 | CS | 1,380 | severe PS | PBPV at 24 days | mild PS |
| 14 | PS | III | 17.5 | 39.4 | vaginal | 3,000 | severe PS | PBPV at 7 days | normal |
| 16 | PS | III | 16.4 | 31.3 | CS | 1,930 | normal | no | – |
| 17 | PA | III | 24.5 | 32.0 | CS | 1,630 | normal | no | – |
| 20 | PS | I | 19.6 | 31.4 | vaginal | 1,790 | severe PS | PBPV at 16 days | normal |
| 21 | PS | III | 17.1 | 34.5 | vaginal | 1,950 | severe PS | PBPV at 20 days | mild PS |
| 22 | PS | III | 32.2 | 35.2 | CS | 2,250 | normal | no | – |
| 23 | PA | III | 15.5 | 32.4 | CS | 1,900 | normal | no | – |
| 25 | PS | III | 17.2 | 30.5 | CS | 1,600 | severe PS | PBPV at 21 days | normal |
| 27 | PS | III | 25.5 | 34.4 | vaginal | 2,300 | severe PS | PBPV at 10 days | normal |
| 28 | PA | III | 26.6 | 36.2 | CS | 2,330 | normal | no | – |

CS = Cesarean section; RV = right ventricle.

Cardiopatía en STFF

Feto receptor




Fig. 2. Follow-up of recipient twins with PS/PA after laser surgery. IUFD = Intrauterine fetal death.

Ortiz JU, Masoller N, Gómez O, Bennasar M, Eixarch E, Lobmaier SM, Crispi F, Gratacos E, Martinez JM. Rate and Outcomes of Pulmonary Stenosis and Functional Pulmonary Atresia in Recipient Twins with Twin-Twin Transfusion Syndrome. *Fetal Diagn Ther*. 2017;41(3):191-196.

Cardiopatía en STFF

Feto receptor

Table 1 Ultrasound findings at time of fetal intervention in 14 complicated monochorionic twin pregnancies with a postnatal diagnosis of right ventricular outflow tract obstruction (RVOTO)

| Case | Diagnosis | Twin with RVOTO | Intervention | GA at intervention (weeks) | Intertwin EFW discordance (%) | DV flow in A-wave | Cardiomegaly | Tricuspid insufficiency | Pericardial effusion |
|------|-------------|-----------------|--------------|----------------------------|-------------------------------|-------------------|--------------|-------------------------|----------------------|
| 1 | TTTS QS-II | Recipient | FLC | 15 + 6 | 22.1 | Positive | No | No | No |
| 2a | TTTS QS-III | Donor | FLC | 19 + 6 | 30.5 | NK | NK | NK | NK |
| 2b | TTTS QS-III | Recipient | FLC | 19 + 6 | 30.5 | Reversed | Yes | No | Yes |
| 3 | TTTS QS-III | Recipient | FLC | 16 + 0 | 37.7 | Absent | No | No | No |
| 4 | TTTS QS-III | Recipient | FLC | 20 + 0 | 33.4 | Reversed | No | No | Yes |
| 5 | TTTS QS-III | Recipient | FLC | 17 + 2 | 26.3 | Positive | No | No | No |
| 6 | TTTS QS-III | Recipient | FLC | 14 + 3 | 4.0 | Positive | No | No | No |
| 7 | TTTS QS-IV | Recipient | FLC | 22 + 3 | 6.1 | Reversed | No | No | Yes |
| 8 | TTTS QS-III | Recipient | FLC | 19 + 5 | 29.3 | Reversed | Yes | No | No |
| 9 | TTTS QS-III | Recipient | FLC | 14 + 4 | 23.5 | Reversed | Yes | NK | Yes |
| 10 | TTTS QS-III | Recipient | FLC | 16 + 1 | 32.1 | Reversed | No | Yes | No |
| 11 | TTTS QS-IV | Recipient | FLC | 15 + 5 | 5.8 | Reversed | Yes | Yes | Yes |
| 12 | sIUGR | Larger | None | — | — | — | — | — | — |
| 13 | sIUGR* | Larger | UCC | 18 + 5 | 45.6 | Positive | Yes | NK | Yes |
| 14 | sIUGR† | Larger | UCC | 18 + 0 | 36.8 | Positive | No | NK | Yes |

*sIUGR twin with abnormal cerebellum and hydrocephalus. †sIUGR twin with omphalocele and hydrocephalus. DV, ductus venosus; EFW, estimated fetal weight; FLC, fetoscopic laser coagulation of anastomoses; GA, gestational age; NK, not known (missing data); QS, Quintero Stage; sIUGR, selective intrauterine growth restriction; TTTS, twin-to-twin transfusion syndrome; UCC, selective feticide by umbilical cord coagulation.

Cardiopatía en STFF

Feto receptor

Table 2 Details of diagnosis and treatment of monochorionic twin pregnancies with postnatal diagnosis of right ventricular outflow tract obstruction (RVOTO)

| Case | GA at delivery (weeks) | Birth weight (g) | Prenatal diagnosis of RVOTO | Postnatal diagnosis of RVOTO | Intervention | Age at intervention (weeks) | Follow-up |
|------|------------------------|------------------|-----------------------------|---|--|-----------------------------|-------------------|
| 1 | 29 + 3 | 1135 | Yes | Severe valvular PS | Balloon valvuloplasty | 4 | A&W |
| 2a | 26 + 3 | 720 | Yes | Valvular PS | Balloon valvuloplasty | 42 | A&W |
| 2b | 26 + 3 | 865 | Yes | Severe valvular PS, hypoplastic RV | None* | | NNND at 1 week |
| 3 | 27 + 0 | 955 | No | Severe valvular PS | Balloon valvuloplasty | 18 | A&W |
| 4 | 38 + 3 | 3420 | Yes | Severe valvular PS, hypoplastic RV | Balloon valvuloplasty, second balloon valvuloplasty† | < 1 | Tay-Sachs disease |
| 5 | 31 + 0 | 1400 | Yes | Severe valvular PS, small RV | Rashkind procedure, balloon valvuloplasty | 4 | A&W |
| 6 | 26 + 5 | 960 | Yes | Mild PS | None | | A&W |
| 7 | 36 + 5 | 2250 | Yes | Mild PS | None | | A&W |
| 8 | 32 + 2 | 1845 | Yes | Severe PS, mild Ebstein's anomaly | Balloon valvuloplasty | 19 | A&W |
| 9 | 39 + 0 | 3260 | Yes | Severe PS, mild Ebstein's anomaly | Balloon valvuloplasty | < 1 | A&W |
| 10 | 29 + 0 | 1205 | Yes | Pulmonary atresia | Balloon valvuloplasty | 3 | A&W |
| 11 | 34 + 3 | 2160 | Yes | Severe PS, massive TI | None‡ | | NNND at 5 days |
| 12 | 34 + 4 | 2630 | Yes | Severe PS, RV hypertrophy | Balloon valvuloplasty | < 1 | A&W |
| 13 | 37 + 3 | 2565 | Yes | Severe PS, RV hypertrophy | Balloon valvuloplasty, BT shunt, 1.5-ventricle repair§ | 6 2.5 years | A&W |
| 14 | 37 + 6 | 3155 | Yes | Severe valvular PS, dysplastic bicuspid valve | Balloon valvuloplasty | 10 | A&W |

Pulmonary stenosis (PS): mild, peak gradient 2–3 m/s; moderate, 3–4 m/s; severe, > 4 m/s). *Neonatal death (NNND) due to prematurity, cardiac failure with cerebral abnormalities and infant respiratory distress syndrome. †Successful balloon valvuloplasty on day 1 with redilatation after 10 weeks because of increasing PS. ‡NNND due to cardiac failure combined with *Escherichia coli* sepsis. §Glenn procedure (bidirectional cavopulmonary shunt). A&W, alive and well; BT shunt, Blalock–Taussig shunt; GA, gestational age; RV, right ventricle; TI, tricuspid insufficiency.

Cardiopatía en STFF

Feto receptor

Table 4 Predicted risk for right ventricular outflow tract obstruction at birth in recipient twins of twin-to-twin transfusion syndrome (TTTS) according to gestational age (GA) at diagnosis, presence of pericardial effusion (PE) and flow in ductus venosus (DV)

| GA at diagnosis of TTTS (weeks) | PE absent | | PE present | |
|---------------------------------|-----------|-------------|------------|-------------|
| | Normal DV | Abnormal DV | Normal DV | Abnormal DV |
| 15 | 4 | 20 | 43 | 82 |
| 16 | 3 | 16 | 35 | 77 |
| 17 | 2 | 12 | 28 | 70 |
| 18 | 2 | 9 | 22 | 63 |
| 19 | 1 | 6 | 17 | 55 |
| 20 | 1 | 5 | 13 | 47 |
| 21 | 1 | 3 | 10 | 39 |
| 22 | 0 | 3 | 7 | 31 |
| 23 | 0 | 2 | 5 | 25 |
| 24 | 0 | 1 | 4 | 19 |
| 25 | 0 | 1 | 3 | 14 |
| 26 | 0 | 1 | 2 | 11 |

Data are given as percentage risk.




Figure 1 Receiver-operating characteristics (ROC) curve for prediction of right ventricular outflow tract obstruction at birth in recipient twin of twin-to-twin transfusion syndrome (TTTS) using model incorporating gestational age at diagnosis of TTTS and presence of pericardial effusion and abnormal flow in the ductus venosus. Area under ROC curve, 0.92.



Tratamiento

SMFM PAPERS

www.AJOG.org

Improved recipient survival with maternal nifedipine in twin-twin transfusion syndrome complicated by TTTS cardiomyopathy undergoing selective fetoscopic laser photocoagulation

Timothy M. Crombleholme, MD; Foong-Yen Lim, MD; Mounira Habli, MD; William Polzin, MD;
Ronald Jaekle, MD; Erik Michelfelder, MD; James Cnota, MD; Chunyan Liu, MS; Mi-Ok Kim, PhD

Crombleholme TM, Lim FY, Habli M, Polzin W, Jaekle R, Michelfelder E, Cnota J, Liu C, Kim MO. Improved recipient survival with maternal nifedipine in twin-twin transfusion syndrome complicated by TTTS cardiomyopathy undergoing selective fetoscopic laser photocoagulation. Am J Obstet Gynecol. 2010 Oct;203(4):397.e1-9.

Tratamiento

TABLE 1
Cincinnati staging system and classifications of recipient cardiomyopathy

| Stage | Donor | Recipient | Recipient cardiomyopathy |
|---|-----------------------------|----------------------------|---|
| Cincinnati staging system | | | |
| I | Oligohydramnios (DVP <2 cm) | Polyhydramnios (DVP >8 cm) | No |
| II | Absent bladder | Bladder seen | No |
| III | Abnormal Doppler findings | Abnormal Doppler findings | None |
| IIIa | | | Mild |
| IIIb | | | Moderate |
| IIIc | | | Severe |
| IV | Hydrops | Hydrops | |
| V | Death | Death | |
| Classifications of recipient cardiomyopathy | | | |
| Variables/cardiomopathy | Mild | Moderate | Severe |
| Atrioventricular valve regurgitation | Mild | Moderate | Severe |
| Right/left ventricular hypertrophy | Mild | Moderate | Severe |
| Myocardial performance index ^a | >+2 Z-score | >+3 Z-score | >+4 Z-score or severe biventricular dysfunction |
| Left | >0.43 | >0.48 | >0.53 |
| Right | >0.48 | >0.56 | >0.64 |


DVP, deepest vertical pocket.

^a Standards at our institution (mean \pm SD): left = 0.33 ± 0.05 ; right = 0.32 ± 0.08 .

Crombleholme. Maternal nifedipine improves recipient survival in TTTS. *Am J Obstet Gynecol* 2010.

Tratamiento

FIGURE 1
Effect on survival of maternal nifedipine



The *y axis* is the percent survival to birth. On the *x axis* are the treatment groups. *All* represents the entire cohort; *stage IIIA* and *IIIB* represent the recipient outcomes by stage. The *open columns* represent the nifedipine-treated group; the *closed columns* represent the gestational age- and stage-matched control subjects. Because there was no statistically significant difference in survival for stages *IIIC* and *IV*, they are not depicted. The *single asterisk* indicates a probability value of .017; the *double asterisk* indicates a probability value of $\leq .021$; the *triple asterisk* indicates a probability value of .014.

Crombleholme. Maternal nifedipine improves recipient survival in TTTS. Am J Obstet Gynecol 2010.

TABLE 5**Summary of Cardiovascular Considerations for Twins Surviving TTTS**

| For 'ex-recipient' | For 'ex-donor' |
|--|---|
| Resolving cardiomyopathy | |
| Right ventricular outflow tract obstruction –unpredictable response to treatment | Coarctation of the aorta – difficult to exclude antenatally |
| Blood pressure | Blood pressure |
| Persistent pulmonary hypertension of the newborn | Cardiac consequences of severe IUGR |



Cardiopatías en Síndrome de Transfusión Feto-fetal (STFF)

Dr. Pablo Silva Labarca
Becado Medicina Materno Fetal
Universidad de Chile